ReviewCancers2026
Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution. While the etiology of other Kaposi's sarcoma (KS) variants is well established, the underlying mechanisms of CKS appear multifactorial, with several risk factors, among which advanced age and male sex are most significant. Due to the rarity of CKS and its often indolent clinical course, clinical trials are sparse, and current knowledge of therapeutic approaches remains limited. Most available clinical trials and practice guidelines focus on human immunodeficiency virus (HIV) -related Kaposi sarcoma. Therefore, specific recommendations for the classic form are restricted and rely on a low level of evidence, as categorized by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, making disease management more challenging. Current approaches to treating CKS include both local and systemic therapies, selected based on disease stage, patient comorbidities, and individual preferences. Systemic treatment options may include immunotherapy, chemotherapy, or antiangiogenic agents. This review summarizes current management strategies and highlights emerging therapeutic approaches for CKS. It aims to support clinicians in optimizing therapeutic decision-making, including the use of novel and investigational therapies. Although several novel therapies are currently under investigation in clinical trials, significant gaps remain. Therefore, further research is needed to improve disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.